

Know her risk of cervical cancer with the cobas[®] HPV test

HPV DNA primary screening
to advance cervical cancer prevention

Only cobas[®] HPV test
is CE-IVD marked and FDA-approved
for all three screening options

- ✓ ASC-US reflex
- ✓ Co-testing
- ✓ Primary screen




Evidence For change

Pap cytology accuracy is related to a woman's age

Comparison of Pap cytology performance vs. screening age

Confirmed \geq CIN3 in women ages 25-50+ yrs in ATHENA study (n=40,901)¹




Time for advancement is here

- Pap cytology development in the 1940's revolutionized cervical cancer detection but cancer rates are no longer declining
- Modern technology using HPV DNA testing identifies the cause of >99% of cervical cancer

Preventable- yet worldwide >250,000 women die of cervical cancer annually
Earlier detection to preserve cervical health

Cervical disease incidence by age group

Confirmed high-grade disease >CIN3 in women 25-50+ yrs (n=40,901)




Women deserve the most accurate screening test, regardless of age

Providing a **cobas** HPV test provides greater confidence of a woman's future cervical health than a Pap test alone

Greater reassurance of safety with cobas[®] HPV test

cobas[®] HPV test proven superior to Pap cytology screening, in ATHENA study




- **cobas[®] HPV test** is the superior predictor of cervical cancer risk compared head-to-head with Pap cytology^{3,4}
- Proven in the ATHENA study, in over 47,000 women ages 21-65 years³

Extensive evidence to genotype HPV 16 and HPV 18


Cervical disease by genotype; 10-year cumulative incidence rate

Disease \geq CIN3 in women 30+ yrs with normal Pap cytology at baseline (n= 12,976)




Extensive clinical evidence
>123,000 women studied with cobas HPV test

cobas HPV test is optimized for accurate actionable results



HPV first-line for greatest screening sensitivity

Simplify management, treat the right women sooner



Global Guidelines support HPV screening first-line

- ACOG, ASCCP, SGO, WHO, EU, + numerous national guidelines

Trust cobas® HPV test for reliable results


<p>✓ Protection from False Negatives</p> <p>Internal cellular control: β-globin = confidence a negative result is truly negative</p>	<p>✓ Confidence of HPV DNA</p>
<p>✓ Protection from False Positives</p> <p>No cross-reactivity⁶, unlike other HPV tests = conclusive HPV16 and HPV18 genotyping</p>	<p>>20yr real-world experience using HPV DNA (limited data for mRNA)⁷</p> <p>Global professional guidelines support DNA for HPV screening specifically⁸⁻¹¹</p>

DNA vs. RNA based HPV testing

cobas® HPV DNA test, optimised for screening

DNA screening identifies more women at risk of cervical cancer

Cervical cancer progression by Human Papillomavirus (HPV)




Detecting HPV DNA identifies at-risk infections at all stages some of these women will be missed by mRNA tests.

43%

of high-risk HPV+ samples identified by a clinically validated DNA-based HPV test, but reported negative by mRNA test²

Sensitivity is vital in Primary HPV screening



Confidence backed by clinical evidence.

Clinical data overwhelmingly supports testing with HPV DNA.

HPV DNA Clinical Studies



mRNA Clinical Studies



“ Additional longitudinal data is required to assess the primary-screening suitability of tests that target molecules other than HPV DNA.¹⁴

-Cuzick et al. (2013)

HPV16and18.com

COBAS and CINTEC are trademarks of Roche.
 ©2017 Roche 0000 0817 RMDPCASFC0000

cobas[®]
HPV test

گروه علمی آزمایشگاه دنا

دکتر مسعود گرشاسبی، دکتر سهیلا سرمدی، دکتر نوید المدنی، دکتر علیرضا قنادان،
 دکتر محمدرضا آراسته، دکتر پانته آروحانی، دکتر راضیه خالصی، دکتر محمدرضا حکمت

تهران، آزمایشگاه دنا (نیلوفر سابق)، خیابان ولیعصر، بین بیمارستان دی و
 پل همت، خیابان نیلو، نبش بن بست دوم
 تلفن: ۴۳۹۳۶

www.DNA-Lab.ir